Market Sentiment Around Loss-Making Amoéba S.A. (EPA:ALMIB)

We feel now is a pretty good time to analyse Amoéba S.A.'s (EPA:ALMIB) business as it appears the company may be on the cusp of a considerable accomplishment. Amoéba S.A. develops biological products and services for the treatment of microbiological risk in the sectors of water, health, and plant protection in France. With the latest financial year loss of €8.3m and a trailing-twelve-month loss of €12m, the €25m market-cap company amplified its loss by moving further away from its breakeven target. The most pressing concern for investors is Amoéba's path to profitability – when will it breakeven? We've put together a brief outline of industry analyst expectations for the company, its year of breakeven and its implied growth rate.

We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

According to the 2 industry analysts covering Amoéba, the consensus is that breakeven is near. They anticipate the company to incur a final loss in 2026, before generating positive profits of €550k in 2027. The company is therefore projected to breakeven just over a year from now. In order to meet this breakeven date, we calculated the rate at which the company must grow year-on-year. It turns out an average annual growth rate of 71% is expected, which is rather optimistic! If this rate turns out to be too aggressive, the company may become profitable much later than analysts predict.

Given this is a high-level overview, we won’t go into details of Amoéba's upcoming projects, though, keep in mind that by and large a high forecast growth rate is not unusual for a company that is currently undergoing an investment period.

Check out our latest analysis for Amoéba

Before we wrap up, there’s one issue worth mentioning. Amoéba currently has negative equity on its balance sheet. Accounting methods used to deal with losses accumulated over time can cause this to occur. This is because liabilities are carried forward into the future until it cancels. Oftentimes, losses exist only on paper but other times, it can be a red flag.

Next Steps:

This article is not intended to be a comprehensive analysis on Amoéba, so if you are interested in understanding the company at a deeper level, take a look at Amoéba's company page on Simply Wall St. We've also put together a list of relevant aspects you should look at:

1. Valuation: What is Amoéba worth today? Has the future growth potential already been factored into the price? The intrinsic value infographic in our free research report helps visualize whether Amoéba is currently mispriced by the market.
2. Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on Amoéba’s board and the CEO’s background.
3. Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.